Identification
- Summary
-
Fusidic acidis a topical antibacterial agent used to prevent and treat mild to moderate skin infections caused by susceptible bacteria.
- Brand Names
-
Fucibet, Fucidin, Fucithalmic
- Generic Name
- Fusidic acid
- DrugBank Accession Number
- DB02703
- Background
-
An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
-
Structure for Fusidic acid (DB02703)
- Weight
-
Average: 516.7092
Monoisotopic: 516.345089268 - Chemical Formula
- C3.1H48O6
- Synonyms
-
- Acide fusidique
- Acido fusidico
- Acidum fusidicum
- Fucidate
- Fucidin acid
- Fusidate
- Fusidic acid
- Fusidine
- Ramycin
- External IDs
-
- NSC-56192
- SQ 16,603
- SQ-16603
Pharmacology
- Indication
-
For the treatment of bacterial infections.
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Associated Conditions
-
- Bacterial Conjunctivitis
- Eye and eyelid infections
- Fungal skin infection
- Skin Infections caused by Corynebacterium minutissimum infection
- Skin Infections caused by Staphylococcus Aureus
- Skin Infections caused by Streptococcus Infection
- Stye
- Bacterial skin infections
- Cutaneous dermatophyte infection
- Eczematous rash
- Mild Atopic dermatitis
- Mild Dermatitis caused by Staphylococcus aureusis
- Moderate Atopic dermatitis
- Moderate Dermatitis caused by Staphylococcus aureusis
- Ocular bacterial infections
- Susceptible Bacterial Infections
- Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support. - Pharmacodynamics
-
Fusidic acid is a bacteriostatic antibiotic and helps prevent bacterial growth while the immune system clears the infection.
- Mechanism of action
-
Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.
Target Actions 殖器官nism AElongation factor G inhibitorThermus thermophilus UChloramphenicol acetyltransferase inhibitorSalmonella typhi UChloramphenicol acetyltransferase 3 inhibitorEscherichia coli - Absorption
-
Sodium fusidic acid tablets have a 91% oral bioavailability. Absorption of the film-coated tablets is complete when compared to a solution, however oral absorption is variable. Oral fusidic acid hemihydrate (suspension) achieved a 22.5% bioavailability in pediatric patients following a 20 milligram/kilogram dose.
- Volume of distribution
-
Not Available
- Protein binding
-
97 to 99%
- Metabolism
-
Metabolites include dicarboxylic ester/acid, 3-keto fusidic acid, hydroxy fusidic acid, glucuronide fusidic acid and a glycol metabolite.
Hover over products below to view reaction partners
- Route of elimination
-
Not Available
- Half-life
-
Approximately 5 to 6 hours in adults.
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data. - Toxicity
-
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The metabolism of 1,2-Benzodiazepine can be decreased when combined with Fusidic acid. Abametapir The serum concentration of Fusidic acid can be increased when it is combined with Abametapir. Abatacept The metabolism of Fusidic acid can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Fusidic acid. Abiraterone The metabolism of Fusidic acid can be decreased when combined with Abiraterone. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Fusidic acid. Acebutolol The metabolism of Acebutolol can be decreased when combined with Fusidic acid. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Fusidic acid. Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Fusidic acid. Acipimox The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Acipimox. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
-
- Take with food. Food reduces irritation.
Products
-
Drug product information from 10+ global regionsOur datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions. - Product Ingredients
-
Ingredient UNII CAS InChI Key Fucidate sodium J7P3696BCQ 751-94-0 HJHVQCXHVMGZNC-JCJNLNMISA-M Fusidic acid hemihydrate W540G73230 172343-30-5 CSXHKOSAWQTJBT-YDYKLMMDSA-N - International/Other Brands
- Fucidine/Fudic/Taksta
- 品牌名称的处方产品
-
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Fucidin Cream 2% Cream 2 % Topical Leo Pharma 1984-12-31 Not applicable Canada 
Fucidin Film Coated Tab 250mg Tablet 250 mg Oral Leo Pharma 1991-12-31 2009-06-05 Canada Fucidin Intertulle 2% Dressing 2 % Topical Leo Pharma 1984-12-31 2004-07-23 Canada Fucidin Leo Sus 246mg/5ml 奥sion 246 mg / 5 mL Oral Leo Pharma 1980-12-31 2004-07-23 Canada Fucidin Ointment 2% Ointment 2 % Topical Leo Pharma 1984-12-31 Not applicable Canada Fucithalmic Solution / drops 1 % w/w Ophthalmic Amdipharm Limited 2001-08-07 2017-07-17 Canada Fucithalmic Solution / drops 1 % w/w Ophthalmic Amdipharm Limited 2001-08-29 Not applicable Canada - Generic Prescription Products
-
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Taro-fusidic Acid Cream 2 % w/w Topical Taro Pharmaceuticals, Inc. Not applicable Not applicable Canada - Over the Counter Products
-
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image DIFUSIN Ointment 2 %w/w Topical บริษัท ฟาร์มาแลนด์ (1982) จำกัด 2007-03-20 2020-09-29 Thailand 
Fucidin Ointment 20 mg/1g Topical Lydia Co., Ltd. 2019-10-08 Not applicable US 
Fucidin Ointment 20 mg/1g Topical OASIS TRADING 2018-11-21 Not applicable US Fucidin Ointment 20 mg/1g Topical I World Pharmaceutical Co., Ltd. 2019-10-08 Not applicable US ฟิวซิดิน Ointment 2 %w/w Topical บริษัท ดีเคเอสเอช (ประเทศไทย) จำกัด 2010-03-11 Not applicable Thailand ฟิวซิดิน Cream 2 %w/w Topical บริษัท ดีเคเอสเอช (ประเทศไทย) จำกัด 2010-03-11 Not applicable Thailand ลูซิน่าร์ ครีม Cream 2 %w/w Topical บริษัท สหการโอสถ (1996) จำกัด จำกัด 2008-12-21 Not applicable Thailand เจิมมีดิก (ครีม) Cream 2 %w/w Topical บริษัท โรงงานเภสัชกรรมแอตแลนติค จำกัด 2015-10-05 Not applicable Thailand แอ็กเซล ฟูซิดิก แอซิด ครีม Cream 2 %w/w Topical บริษัท ฟาร์มาแลนด์ (1982) จำกัด 2018-03-19 Not applicable Thailand - Mixture Products
-
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image DEFUZIN-B CREAM Fusidic acid(20 mg/g)+Betamethasone(1 mg/g) Cream Topical APEX PHARMA MARKETING PTE. LTD. 2019-05-13 Not applicable Singapore DEFUZIN-B CREAM Fusidic acid(2 % w/w)+Betamethasone valerate(0.1 % w/w) Cream Topical XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD 2020-09-08 Not applicable Malaysia 
DERMOTRIZOL ® Fusidic acid(2.04 g)+Dexamethasone(0.054 g)+Ketoconazole(2.04 g) Cream Topical COLOMPACK S.A. 2018-05-02 Not applicable Colombia 
FOBANCORT CREAM Fusidic acid(2 % w/w)+Betamethasone(0.05 % w/w) Cream Topical ZUELLIG PHARMA PTE. LTD. 2001-10-22 Not applicable Singapore FOBANCORT OINTMENT Fucidate sodium(2 % w/w)+Betamethasone dipropionate(0.064 % w/w) Ointment Topical ZUELLIG PHARMA PTE. LTD. 2001-05-10 Not applicable Singapore Fucibet Fusidic acid(2 % w/w)+Betamethasone valerate(0.1 % w/w) Cream Topical Leo Pharma 2018-10-03 Not applicable Canada Fucibet Lipid 20 mg/g + 1 mg/g Creme Fusidic acid(20 mg/g)+Betamethasone(1 mg/g) Cream Topical Leo Pharma 2015-12-30 Not applicable Austria 
FUCICORT 20 MG/G + 1 MG/G KREM, 30 G Fusidic acid(20 mg/g)+Betamethasone valerate(1 mg/g) Cream Topical ABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey 
FUCICORT CREAM Fusidic acid(20 mg/g)+Betamethasone valerate(1 mg/g) Cream Topical LEO PHARMA ASIA PTE LTD 1988-03-05 Not applicable Singapore FUCICORT(R) Fusidic acid(2 g/100g)+Betamethasone valerate(100 mg/100g) Cream บริษัท ดีเคเอสเอช (ประเทศไทย) จำกัด 2010-03-11 Not applicable Thailand - Unapproved/Other Products
-
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image FUCIBEST % 2 20 GR KREM Fusidic acid(2 %) Cream Topical TRİOZER İLAÇ KİM. KOZMETİK SAĞ. HİZM. SAN. VE TİC. LTD. ŞTİ. 2020-08-14 Not applicable Turkey Fucidin Fucidate sodium(20毫克/ 1 g) Ointment Topical Lydia Co., Ltd. 2019-10-08 Not applicable US Fucidin Fucidate sodium(20毫克/ 1 g) Ointment Topical OASIS TRADING 2018-11-21 Not applicable US Fucidin Fucidate sodium(20毫克/ 1 g) Ointment Topical I World Pharmaceutical Co., Ltd. 2019-10-08 Not applicable US
Categories
- ATC Codes
-
S01AA13 — Fusidic acid
D09AA02 — Fusidic acid
- D09AA — Medicated dressings with antiinfectives
- D09A — MEDICATED DRESSINGS
- D09 — MEDICATED DRESSINGS
- D — DERMATOLOGICALS
- J01XC — Steroid antibacterials
- J01X — OTHER ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
-
- Agents Causing Muscle Toxicity
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antibiotics for Topical Use
- Antiinfectives for Systemic Use
- BCRP/ABCG2 Inhibitors
- BSEP/ABCB11 Inhibitors
- Cholestadienes
- Cholestadienols
- Cholestanes
- Cholestenes
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (moderate)
- Cytochrome P-450 CYP2D6 Substrates
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (moderate)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Substrates
- Dermatologicals
- Enzyme Inhibitors
- Fused-Ring Compounds
- Lipids
- Medicated Dressings
- Medicated Dressings With Antiinfectives
- Membrane Lipids
- OATP1B1/SLCO1B1 Inhibitors
- Ophthalmologicals
- Other Miscellaneous Antibacterial Agents
- Protein Synthesis Inhibitors
- Sensory Organs
- Steroid Antibacterials
- Steroids
- Sterols
- UGT1A1 Substrates
- Chemical TaxonomyProvided byClassyfire
-
- Description
- This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
- Kingdom
- 殖器官nic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Steroid esters
- Direct Parent
- Steroid esters
- Alternative Parents
- 3.-alpha-hydroxysteroids/11-alpha-hydroxysteroids/Medium-chain fatty acids/Methyl-branched fatty acids/Hydroxy fatty acids/Unsaturated fatty acids/Dicarboxylic acids and derivatives/Secondary alcohols/Cyclic alcohols and derivatives/Carboxylic acid esters show 4 more
- Substituents
- 11-alpha-hydroxysteroid/11-hydroxysteroid/3.-alpha-hydroxysteroid/3-hydroxysteroid/Alcohol/Aliphatic homopolycyclic compound/Branched fatty acid/Carbonyl group/Carboxylic acid/Carboxylic acid derivative show 16 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 3.alpha-hydroxy steroid, alpha,beta-unsaturated monocarboxylic acid, sterol ester, steroid acid, 11alpha-hydroxy steroid, steroid antibiotic (CHEBI:29013)/Prostostane and fusidane triterpenoids (LMPR0106040001)
- Affected organisms
-
- Enteric bacteria and other eubacteria
Chemical Identifiers
- UNII
- 59XE10C19C
- CAS number
- 6990-06-3
- InChI Key
- IECPWNUMDGFDKC-MZJAQBGESA-N
- InChI
-
InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
- IUPAC Name
-
2-[(1Z,2S,3aS,3bS,5aS,6S,7R,9aS,9bS,10R,11aR)-2-(acetyloxy)-7,10-dihydroxy-3a,3b,6,9a-tetramethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-ylidene]-6-methylhept-5-enoic acid
- SMILES
-
[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C(O)=O
References
- Synthesis Reference
-
Vanangamudi Subramaniam Sulur, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Haridas Sankar, Selvaraj Balkrishnan, " PROCESS TO MAKE FUSIDIC ACID CREAM." U.S. Patent US20110301138, issued December 08, 2011.
US20110301138 - 一般引用
-
- Health Canada Product Monograph: Fucidin (fucidic acid) for topical use [Link]
- External Links
-
- Human Metabolome Database
- HMDB0015570
- KEGG Drug
- D04281
- KEGG Compound
- C06694
- PubChem Compound
- 3.000226
- PubChem Substance
- 46505364
- ChemSpider
- 2271900
- BindingDB
- 58924
- 113608
- ChEBI
- 29013
- ChEMBL
- CHEMBL374975
- ZINC
- ZINC000008143796
- Therapeutic Targets Database
- DAP001008
- PharmGKB
- PA164749648
- PDBe Ligand
- FUA
- Wikipedia
- Fusidic_acid
- PDB Entries
- 1q23/1qca/2vuf/4v5f/4v5m/4v5n/4v7b/4v8u/4v9l/4v9m… show 12 more
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count 4 Completed Treatment Diabetes Mellitus 1 4 Not Yet Recruiting Treatment Infective Endocarditis (IE) 1 4 Terminated Treatment Impetigo 1 4 Unknown Status Treatment Inflammation of the Eyelids 1 3. Completed Treatment Acute Bacterial Skin and Skin Structure Infection (ABSSSI) 1 3. Completed Treatment Non-Small Cell Lung Cancer, Lung Cancer, Cancer 1 3. Terminated Treatment Infected Atopic Dermatitis/Eczema 1 3. Unknown Status Prevention Keloids Scars/Scars, Hypertrophic 1 2 Completed Treatment Bacterial skin infections 1 2 Not Yet Recruiting Treatment Cystic Fibrosis (CF)/Cystic Fibrosis Pulmonary Exacerbation 1
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
-
Form Route Strength Powder, for suspension Oral 5 g Solution Conjunctival; Ophthalmic 10 mg Cream Topical 2 g Cream Topical 2.0 % W/W Cream Topical 2.00 % w/w Capsule 250 MG Ointment Topical 2 %w/w Cream Topical 2.03 % w/w Ointment Topical 2.04 % w/w Cream Topical 2 % w/w Ointment Topical 2 % w/w Cream Topical 0.05 % w/w Ointment Topical Ointment Topical 20 mg/g Cream Topical Cream Topical 0.1 g Cream Topical 20 MG/G Ointment Topical 20 mg/1g Tablet, film coated Oral 250 mg Tablet, film coated Oral 500 mg Tablet, film coated Oral Cream Topical 2 % Tablet Oral 250 mg Cream Cutaneous Cream Topical 20 mg/g Dressing Topical 2 % Kit Intravenous 奥sion Oral 246 mg / 5 mL Ointment Topical 2 % Tablet Oral Ointment Topical 2 g Drug delivery system Topical 3.0 mg Ointment Topical 20 mg Cream Topical 2 mg 奥sion / drops Ophthalmic 1 % Solution / drops Ophthalmic 1 % w/w Solution / drops Ophthalmic 1 % Gel Ophthalmic 10 mg/g Solution Ophthalmic 10 mg/g 奥sion / drops Ophthalmic 奥sion Ophthalmic 10 mg Ointment Topical Solution / drops Ophthalmic 1.02 % Cream Topical 20 mg Cream Topical Injection, solution, concentrate Intravenous Gel Ophthalmic Solution / drops Ophthalmic Solution / drops Ophthalmic 50 mg Injection Intravenous 500 mg Pill Tablet, coated Oral 奥sion Topical 20 mg Injection, solution Intravenous Cream Tablet, coated Oral 250 mg Cream Topical 2 %w/w - Prices
-
Unit description Cost Unit Fucidin 2 % Cream 0.66USD g Fucidin 2 % Ointment 0.66USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only. - Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
-
Property Value Source melting point (°C) 192.5 °C PhysProp pKa 5.35 MERCK INDEX (1996) - Predicted Properties
-
Property Value Source Water Solubility 0.00521 mg/mL ALOGPS logP 4.97 ALOGPS logP 4.42 Chemaxon logS -5 ALOGPS pKa (Strongest Acidic) 4.46 Chemaxon pKa (Strongest Basic) -0.2 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3. Chemaxon Polar Surface Area 104.06 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 144.12 m3.·mol-1 Chemaxon Polarizability 59.76 Å3. Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
-
Property Value Probability Human Intestinal Absorption + 0.9691 Blood Brain Barrier + 0.7909 Caco-2 permeable - 0.6089 P-glycoprotein substrate Substrate 0.8165 我22抑制剂 Non-inhibitor 0.6004 我22抑制剂I Inhibitor 0.7848 Renal organic cation transporter Non-inhibitor 0.8424 CYP450 2C9 substrate Non-substrate 0.8218 CYP450 2D6 substrate Non-substrate 0.9349 CYP450 3A4 substrate Substrate 0.798 CYP450 1A2 substrate Non-inhibitor 0.9337 CYP450 2C9 inhibitor Non-inhibitor 0.8834 CYP450 2D6 inhibitor Non-inhibitor 0.9544 CYP450 2C19 inhibitor Non-inhibitor 0.9347 CYP450 3A4 inhibitor Non-inhibitor 0.76 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.819 Ames test Non AMES toxic 0.8305 Carcinogenicity Non-carcinogens 0.9508 Biodegradation Not ready biodegradable 0.9753 Rat acute toxicity 3..5929 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9403 hERG inhibition (predictor II) Non-inhibitor 0.7564
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
-
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - Linear Ion Trap , negative LC-MS/MS splash10-05fr-0002900000-512150f35d55c73b9e09 MS/MS Spectrum - Linear Ion Trap , positive LC-MS/MS splash10-004i-0000900000-eecd35dcbd3fede944c2 MS/MS Spectrum - Linear Ion Trap , positive LC-MS/MS splash10-0002-0000900000-4a266f99ada066a14539
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
insights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- 殖器官nism
- Thermus thermophilus
- Pharmacological action
-
Yes
- Actions
-
Inhibitor
- General Function
- Translation elongation factor activity
- Specific Function
- Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) ...
- Gene Name
- fusA
- Uniprot ID
- P13551
- Uniprot Name
- Elongation factor G
- 分子量
- 76878.69 Da
References
- Lannergard J, Norstrom T, Hughes D: Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65. doi: 10.1128/AAC.00871-08. Epub 2009 Mar 16. [Article]
- Chen Y, Koripella RK, Sanyal S, Selmer M: Staphylococcus aureus elongation factor G--structure and analysis of a target for fusidic acid. FEBS J. 2010 Sep;277(18):3789-803. doi: 10.1111/j.1742-4658.2010.07780.x. Epub 2010 Aug 13. [Article]
- Gao YG, Selmer M, Dunham CM, Weixlbaumer A, Kelley AC, Ramakrishnan V: The structure of the ribosome with elongation factor G trapped in the posttranslocational state. Science. 2009 Oct 30;326(5953):694-9. doi: 10.1126/science.1179709. [Article]
- Kind
- Protein
- 殖器官nism
- Salmonella typhi
- Pharmacological action
-
Unknown
- Actions
-
Inhibitor
- General Function
- Chloramphenicol o-acetyltransferase activity
- Specific Function
- This enzyme is an effector of chloramphenicol resistance in bacteria.
- Gene Name
- cat
- Uniprot ID
- P62580
- Uniprot Name
- Chloramphenicol acetyltransferase
- 分子量
- 25663.08 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Murray IA, Cann PA, Day PJ, Derrick JP, Sutcliffe MJ, Shaw WV, Leslie AG: Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site. J Mol Biol. 1995 Dec 15;254(5):993-1005. [Article]
- Bennett AD, Shaw WV: Resistance to fusidic acid in Escherichia coli mediated by the type I variant of chloramphenicol acetyltransferase. A plasmid-encoded mechanism involving antibiotic binding. Biochem J. 1983 Oct 1;215(1):29-38. [Article]
- Day PJ, Murray IA, Shaw WV: Properties of hybrid active sites in oligomeric proteins: kinetic and ligand binding studies with chloramphenicol acetyltransferase trimers. Biochemistry. 1995 May 16;34(19):6416-22. [Article]
- Kind
- Protein
- 殖器官nism
- Escherichia coli
- Pharmacological action
-
Unknown
- Actions
-
Inhibitor
- General Function
- Chloramphenicol o-acetyltransferase activity
- Specific Function
- This enzyme is an effector of chloramphenicol resistance in bacteria.
- Gene Name
- cat3
- Uniprot ID
- P00484
- Uniprot Name
- Chloramphenicol acetyltransferase 3
- 分子量
- 24993.32 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Murray IA, Cann PA, Day PJ, Derrick JP, Sutcliffe MJ, Shaw WV, Leslie AG: Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site. J Mol Biol. 1995 Dec 15;254(5):993-1005. [Article]
- Bennett AD, Shaw WV: Resistance to fusidic acid in Escherichia coli mediated by the type I variant of chloramphenicol acetyltransferase. A plasmid-encoded mechanism involving antibiotic binding. Biochem J. 1983 Oct 1;215(1):29-38. [Article]
- Day PJ, Murray IA, Shaw WV: Properties of hybrid active sites in oligomeric proteins: kinetic and ligand binding studies with chloramphenicol acetyltransferase trimers. Biochemistry. 1995 May 16;34(19):6416-22. [Article]
Enzymes
- Kind
- Protein
- 殖器官nism
- Humans
- Pharmacological action
-
Unknown
- Actions
-
SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- 分子量
- 55768.94 Da
References
- Lin XX, Lian GH, Xu Y, Zhao Q, Xiao J, Peng SF, Xiao MF, Ouyang DS, Tan ZR, Wang YC, Peng JB, Zhang W, Chen Y: The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. Xenobiotica. 2018 Oct;48(10):999-1005. doi: 10.1080/00498254.2017.1390628. Epub 2017 Nov 10. [Article]
- Chen D, Lin XX, Zhao Q, Xiao J, Peng SF, Xiao MF, Ouyang DS, Tan ZR, Wang YC, Peng JB, Zhang W, Chen Y: Screening of drug metabolizing enzymes for fusidic acid and its interactions with isoform-selective substrates in vitro. Xenobiotica. 2017 Sep;47(9):778-784. doi: 10.1080/00498254.2016.1230795. Epub 2016 Nov 15. [Article]
- Kind
- Protein
- 殖器官nism
- Humans
- Pharmacological action
-
Unknown
- Actions
-
SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- 分子量
- 57342.67 Da
References
- Lin XX, Lian GH, Xu Y, Zhao Q, Xiao J, Peng SF, Xiao MF, Ouyang DS, Tan ZR, Wang YC, Peng JB, Zhang W, Chen Y: The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. Xenobiotica. 2018 Oct;48(10):999-1005. doi: 10.1080/00498254.2017.1390628. Epub 2017 Nov 10. [Article]
- Chen D, Lin XX, Zhao Q, Xiao J, Peng SF, Xiao MF, Ouyang DS, Tan ZR, Wang YC, Peng JB, Zhang W, Chen Y: Screening of drug metabolizing enzymes for fusidic acid and its interactions with isoform-selective substrates in vitro. Xenobiotica. 2017 Sep;47(9):778-784. doi: 10.1080/00498254.2016.1230795. Epub 2016 Nov 15. [Article]
- Gupta A, Harris JJ, Lin J, Bulgarelli JP, Birmingham BK, Grimm SW: Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94. doi: 10.1128/AAC.01335-16. Print 2016 Oct. [Article]
- Kind
- Protein
- 殖器官nism
- Humans
- Pharmacological action
-
Unknown
- Actions
-
Substrate
- General Function
- Steroid binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
- Gene Name
- UGT1A1
- Uniprot ID
- P22309
- Uniprot Name
- UDP-glucuronosyltransferase 1-1
- 分子量
- 59590.91 Da
References
- Gupta A, Harris JJ, Lin J, Bulgarelli JP, Birmingham BK, Grimm SW: Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94. doi: 10.1128/AAC.01335-16. Print 2016 Oct. [Article]
Transporters
- Kind
- Protein
- 殖器官nism
- Humans
- Pharmacological action
-
Unknown
- Actions
-
Inhibitor
- General Function
- Transporter activity
- Specific Function
- Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
- Gene Name
- ABCB11
- Uniprot ID
- O95342
- Uniprot Name
- Bile salt export pump
- 分子量
- 146405.83 Da
References
- Bode KA, Donner MG, Leier I, Keppler D: Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8. [Article]
- Kind
- Protein
- 殖器官nism
- Humans
- Pharmacological action
-
Unknown
- Actions
-
Inhibitor
- General Function
- 有机离子跨膜转运体活动
- Specific Function
- Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
- Gene Name
- ABCC2
- Uniprot ID
- Q92887
- Uniprot Name
- Canalicular multispecific organic anion transporter 1
- 分子量
- 174205.64 Da
References
- Bode KA, Donner MG, Leier I, Keppler D: Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8. [Article]
- Kind
- Protein
- 殖器官nism
- Humans
- Pharmacological action
-
Unknown
- Actions
-
Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- 高容量尿酸盐出口国r功能enal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
- Gene Name
- ABCG2
- Uniprot ID
- Q9UNQ0
- Uniprot Name
- ATP-binding cassette sub-family G member 2
- 分子量
- 72313.47 Da
References
- Gupta A, Harris JJ, Lin J, Bulgarelli JP, Birmingham BK, Grimm SW: Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94. doi: 10.1128/AAC.01335-16. Print 2016 Oct. [Article]
- Kind
- Protein
- 殖器官nism
- Humans
- Pharmacological action
-
Unknown
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
- Gene Name
- SLCO1B1
- Uniprot ID
- Q9Y6L6
- Uniprot Name
- Solute carrier organic anion transporter family member 1B1
- 分子量
- 76447.99 Da
References
- Gupta A, Harris JJ, Lin J, Bulgarelli JP, Birmingham BK, Grimm SW: Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94. doi: 10.1128/AAC.01335-16. Print 2016 Oct. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 19, 2023 09:30